Therapeutic interventions in the study population_
| Extend of surgical procedure, n (%) | ||||
| Lumpectomy | 8 (38.10%) | 5 (22.73%) | 13 (30.23%) | 0.1482 |
| Quadrantectomy | 4 (19.05%) | 4 (18.18%) | 8 (18.6%) | |
| Simple mastectomy | 2 (9.52%) | 5 (22.73%) | 7 (16.28%) | |
| Modified radical mastectomy | 7 (33.33%) | 4 (18.18%) | 11 (25.58%) | |
| No surgery | 0 | 4 (18.18%) | 4 (9.3%) | |
| Adjuvant therapeutic modalities, n (%) | ||||
| Chemotherapy | 12 (44.44%) | 9 (33.33%) | 21 (38.89%) | 0.0593 |
| Radiotherapy | 10 (37.04%) | 5 (18.52%) | 15 (27.78%) | |
| Endocrine therapy | 5 (18.52%) | 13 (48.15%) | 18 (33.33%) | |
Clinicopathological characteristics of the study population_
| Age group (years) | P | |||
|---|---|---|---|---|
| <40 | >80 | Total | ||
| Histological Type, n (%) | ||||
| Ductal invasive | 12 (57.14%) | 13 (59.09%) | 25 (58.14%) | 0.1472 |
| Lobular invasive | 3 (14.29%) | 2 (9.09%) | 5 (11.63%) | |
| Other | 6 (28.57%) | 7 (31.82%) | 13 (30.23%) | |
| Tumor Size (T), n (%) | ||||
| T≤ 2 cm | 7 (33.33%) | 9 (40.90%) | 16 (37.21%) | 0.7546 |
| T > 2 cm | 14 (66.67%) | 13 (59.10%) | 27 (62.79%) | |
| Positive lymph nodes, n (%) | ||||
| 0 lymph nodes | 11 (52.38%) | 12 (54.54%) | 23 (53.49%) | 0.8948 |
| 1–3 lymph nodes | 6 (28.57%) | 5 (22.73%) | 11 (25.58%) | |
| ≥4 lymph nodes | 4 (19.05%) | 5 (22.73%) | 9 (20.93%) | |
| TNM Stage, n (%) | ||||
| I | 4 (19.05%) | 4 (18.18%) | 8 (18.61%) | 0.4609 |
| II | 13 (61.90%) | 11 (50.00%) | 24 (55.81%) | |
| III | 4 (19.05%) | 7 (31.82%) | 11 (25.58%) | |
| Hormone receptor status, n (%) | ||||
| ER+/PR+ | 10 (47.62%) | 11 (50.00%) | 21 (48.84%) | 0.9571 |
| ER−/PR− | 6 (28.57%) | 5 (22.73%) | 11 (25.58%) | |
| ER+/PR− | 3 (14.28%) | 3 (13.64%) | 6 (13.95%) | |
| ER−/PR+ | 2 (9.53%) | 3 (13.64%) | 5 (11.63%) | |
| Histological Grade, n (%) | ||||
| I | 3 (14.29%) | 2 (9.09%) | 5 (11.63%) | 0.4754 |
| II | 5 (23.81%) | 9 (40.91%) | 14 (32.56%) | |
| III | 13 (61.90%) | 11 (50.00%) | 24 (55.81%) | |